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Abstract 
Background: Hypertension (HTN), diabetes mellitus (DM), and dyslipidemia (DL) are well‑known risk factors of 
cardiovascular disease (CVD), but not all patients develop CVDs. Studies have been limited investigating genetic risk 
of CVDs specific to individuals with metabolic diseases. This study aimed to identify disease‑specific and/or common 
genetic loci associated with CVD susceptibility in chronic metabolic disease patients.
Methods: We conducted a genome‑wide association study (GWAS) of a multiple case–control design with data from 
the City Cohort within Health EXAminees subcohort of the Korean Genome and Epidemiology Study (KoGES_HEXA). 
KoGES_HEXA is a population‑based prospective cohort of 173,357 urban Korean adults that had health examina‑
tions at medical centers. 42,393 participants (16,309 HTN; 5,314 DM; 20,770 DL) were analyzed, and each metabolic 
disease group was divided into three CVD case‑controls: coronary artery disease (CAD), ischemic stroke (IS), and 
cardio‑cerebrovascular disease (CCD). GWASs were conducted for each case–control group with 7,975,321 imputed 
single nucleotide polymorphisms using the Phase 3 Asian panel from 1000 Genomes Project, by logistic regression 
and controlled for confounding variables. Genome‑wide significant levels were implemented to identify important 
susceptibility loci.
Results: Totaling 42,393 individuals, this study included 16,309 HTN (mean age [SD], 57.28 [7.45]; 816 CAD, 398 IS, 
and 1,185 CCD cases), 5,314 DM (57.79 [7.39]; 361 CAD, 153 IS, and 497 CCD cases), and 20,770 DL patients (55.34 
[7.63]; 768 CAD, 295 IS, and 1,039 CCD cases). Six genome‑wide significant CVD risk loci were identified, with rela‑
tively large effect sizes: 1 locus in HTN (HTN‑CAD: 17q25.3/CBX8-CBX4 [OR, 2.607; P = 6.37 × 10−9]), 2 in DM (DM‑IS: 
4q32.3/MARCH1-LINC01207 [OR, 5.587; P = 1.34 × 10−8], and DM‑CCD: 17q25.3/RPTOR [OR, 3.511; P = 1.99 × 10−8]), 
and 3 in DL (DL‑CAD: 9q22.2/UNQ6494-LOC101927847 [OR, 2.282; P = 7.78 × 10−9], DL‑IS: 3p22.1/ULK4 [OR, 2.162; 
P = 2.97 × 10−8], and DL‑CCD: 2p22.2/CYP1B1-CYP1B1-AS1 [OR, 2.027; P = 4.24 × 10−8]).
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Background
Cardiovascular disease (CVD) is the leading cause of 
death globally, and the prevalence of cardiovascular dis-
ease is constantly progressing in both developed and 
developing nations [1]. According to a World Health 
Organization report, an estimated 17.9 million people 
died from heart disease and stroke in 2016, representing 
31% of all global deaths, and it was projected that about 
23.6 million people will die from CVDs by 2030 [2]. In 
line with the global trend, economic and social develop-
ments have significantly impacted lifestyles of Koreans; 
CVDs are now one of the main causes of death in Korea, 
accounting for 1 in every 5 deaths [3]. Therefore, inter-
ventions to prevent and reduce cardiovascular risk fac-
tors are warranted.
Epidemiological evidence suggest that CVD is asso-
ciated with age, sex, ethnicity, behavioral risk factors 
(smoking, alcohol use, and low physical activity levels), 
and several chronic metabolic diseases. Among them, 
hypertension (HTN), dyslipidemia (DL), and type 2 dia-
betes (DM) are the most common modifiable risk factors 
for CVD, which is known as the most prevalent cause of 
mortality and morbidity in populations with HTN, DM, 
and DL [4]. Approximately two-thirds of all adults with 
HTN at 30 years of age have a ~ 40% higher risk of experi-
encing a CVD event and systematic reviews have revealed 
that lowering blood pressure greatly reduced major CVD 
events and all-cause mortality, irrespective of the initial 
blood pressure [5]. Patients with DM had a 10% greater 
risk of coronary artery disease (CAD), a 53% greater risk 
of myocardial infarction (MI), and a 58% greater risk of 
stroke compared to those without diagnoses of DM, 
and CVD accounts for approximately half of all deaths 
in patients with DM, largely due to an increased risk of 
stroke and MI [6]. Further, in the INTERHEART study, 
49% of the population-attributable risk of a first MI was 
contributed by DL, and the prevalence of DL was found 
to be between 83 and 87% in Asian patients with CVD 
[7].
There are various biochemical mechanisms that inde-
pendently increase the risk of CVD in people with these 
chronic metabolic diseases. Lipid oxidation is thought to 
be an important determinant of atherosclerosis, which 
leads to CVD; moreover, high levels of low‐density lipo-
protein (LDL) and low levels of high‐density lipopro-
tein (HDL) are associated with MI and stroke in DL [8]. 
Endothelial dysfunction, vascular inflammation, arterial 
remodeling, atherosclerosis, dyslipidemia, and obesity 
are common risk factors for CVD in HTN and DM. In 
addition, upregulation of the renin–angiotensin–aldos-
terone system, oxidative stress, inflammation, and acti-
vation of the immune system contribute to the close 
relationship between DM, HTN, and CVD [9].
However, only limited evidence is available regarding 
the relationship between multiple chronic metabolic 
diseases and CVDs. Furthermore, despite maintaining 
optimal levels of metabolic indices, such as blood pres-
sure, glucose, or lipids, CVDs still remain prevalent in 
individuals with HTN, DM, and DL. Evidence suggest 
that although hyperglycemia contributes to ischemic 
events, it is not the only factor, because both pre-dia-
betes and normoglycemic patients show risk for most 
types of CVD [10]. High-dose statin therapy may pro-
vide some incremental benefit between 10 and 20%; 
nevertheless, statin-treated patients remain at high 
residual risk for future cardiovascular events [11]. This 
suggests that other non-modifiable risk factors, such as 
genetic and genomic variables, need to be considered 
as well.
Genetic factors are important contributors to the 
risk of CVDs; recent genome-wide association studies 
(GWASs) strongly support that genetic susceptibility to 
CVD is largely derived from gene mutations or varia-
tion [12]. Loci nearest a lead single nucleotide polymor-
phism (SNP) was shown to have genome-wide significant 
associations with obesity, blood pressure, lipids, DM, 
CAD, and stroke [13]. However, over the past decade, 
the majority of GWASs for CVDs or related risk factors 
have been conducted in populations with European white 
ancestry and limited evidence is available in Asian pop-
ulations [14]. Furthermore, few analyses focused on the 
genetic differences in CVD susceptibility between indi-
viduals with the same chronic metabolic conditions.
Therefore, we conducted three sets of GWASs 
between case-controls of major CVDs in HTN, DM, 
and DL patient groups using data from the well-known 
nationwide Korean Genome and Epidemiology Study 
(KoGES). We aimed to find genetic pathways linking 
the development of CVD with each metabolic disease 
group; we further aimed to identify the potential pres-
ence of a common pathway leading to CVD among the 
commonly co-existing metabolic conditions.
Conclusions: This study identified 6 susceptibility loci and positional candidate genes for CVDs in HTN, DM, and DL 
patients using an unprecedented study design. 1 locus (17q25.3) was commonly associated with CAD. These associa‑
tions warrant validation in additional studies for potential therapeutic applications.
Keywords: Hypertension, Diabetes mellitus, Dyslipidemia, Cardiovascular disease, Genome‑wide association studies
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Methods
Study populations
Our study used a part of the KoGES dataset obtained 
from the Korean Center for Disease Control and Preven-
tion. The largest cohort of KoGES is the health examina-
tion cohort [KoGES_HEXA], and its dataset consists of 
participants’ medico-pharmacologic history, anthropo-
metric traits, and blood biochemistry traits [15]. Briefly, 
KoGES_HEXA is a population-based prospective cohort 
of 173,357 urban Korean adults that had health exami-
nations at medical centers, recruited from the national 
health examinee registry. Participants were men and 
women, aged 40–69  years from 14 major cities across 
Korea and recruited at baseline between 2004 and 2013. 
A total of 58,701 participants, whose genome-wide SNP 
genotype data were obtained, were included in the city-
based cohort of the KoGES. All participants voluntarily 
signed an informed consent form before the study, and 
the study protocol was approved by the Institutional 
Review Boards (IRB) of the institutions that partici-
pated in KoGES. This study was performed in accord-
ance with the Declaration of Helsinki and approved 
by the IRB of Theragen Etex (Approval Numbers: 
700062-20190819-GP-006-02).
Measurement of anthropometric and laboratory data & 
Definition of lifestyle factors
Study participants completed a standardized medi-
cal history and lifestyle questionnaire and underwent a 
comprehensive health examination by trained medical 
staff according to a standard protocol. Smoking status 
was classified into three groups: participants who had 
smoked over 100 cigarettes throughout their lifetimes 
but had quit before this study were ex-smokers, currently 
smoking were current smokers, and the remaining were 
non-smokers. Drinking status (alcohol intake) was also 
classified into three groups: current drinkers, ex-drink-
ers, and non-drinkers. Regularity of physical activity was 
determined according to whether subjects participated 
regularly in any sports to the point of sweating.
Body mass index (BMI) was calculated as weight in 
kilograms divided by height in meters squared (kg/m2). 
Systolic (SBP) and diastolic blood pressure (DBP) were 
measured twice by a standardized mercury sphygmoma-
nometer (Baumanometer-Standby; W.A. Baum Co. Inc., 
New York, NY, USA). Blood samples were drawn after 
overnight fasting, and venous blood sampling was col-
lected in a plain tube. Biochemical parameters, includ-
ing fasting glucose, hemoglobin A1c (HbA1c), total 
cholesterol, HDL cholesterol, and triglycerides (TG), 
were determined by enzymatic methods (ADVIA 
1650, Siemens, Tarrytown. NY, USA). LDL- choles-
terol was calculated using the Friedewald equation 
(LDL-cholesterol = total cholesterol –HDL- cholesterol 
–[TG/5]).
Definition of study phenotypes
HTN was defined as systolic BP ≥ 140 mmHg or diastolic 
BP ≥ 90  mmHg on health examination, currently taking 
an anti-hypertensive drug, or diagnosed by a physician. 
DM was defined as fasting blood glucose ≥ 126  mg/dl, 
HbA1c ≥ 6.5% (48  mmol/mol), currently taking an anti-
diabetic drug or insulin, or diagnosed by a physician.
DL was defined as either diagnosis by a physician, 
current use of lipid-lowering medication, or accord-
ing to the National Cholesterol Education Program- 
Adult Treatment Panel III (NCEP-ATP III) criteria: 
(1) hypercholesterolemia (serum TC ≥ 240  mg/dl), (2) 
hypertriglyceridemia (serum TG ≥ 200 mg/dl), (3) hyper-
LDL-cholesterolemia (serum LDL-C ≥ 160  mg/dl), (4) 
hypo-HDL-cholesterolemia (serum HDL-C < 40 mg/dl).
Outcome measurements
We defined CAD as the participant-reported history of 
the diagnosis or treatment of angina pectoris or myo-
cardial infarction. Ischemic stroke (IS) was defined in 
the same manner, in that it was based on the partici-
pant-reported history of the diagnosis or treatment of 
ischemic stroke. Cardio-cerebrovascular disease (CCD) 
was defined as the combination of CAD and IS per our 
study outcome definition.
Study design
This study investigated the genetic risk factors of CVDs 
in the patients with metabolic disease (HTN, DM, or 
DL). For this analysis, we applied the exclusion cri-
teria schematically illustrated in Fig.  1: from baseline 
we excluded participants with missing data values, i.e. 
smoking, alcohol, exercise history and body mass index 
(BMI) (n = 471). Subsequently, participants with histo-
ries of malignancy or no response regarding malignancy 
were excluded (n = 2,202). After these exclusions, 56,028 
participants were included; the final sample size for the 
present analysis was 16,313 participants with HTN, 5394 
participants with DM, and 20,788 participants with DL.
Genotyping and quality control procedures
The genotype data were graciously provided by the 
Center for Genome Science, Korea National Institute of 
Health. The genotype data was produced by the Korea 
Biobank Array (Affymetrix, Santa Clara, CA, USA) 
(Moon et  al., 2019, PMID 30718733). The experimen-
tal results of Korea Biobank Array were filtered by the 
quality control procedures of the following criteria: call 
rate higher than 97%, minor allele frequency higher than 
1%, and Hardy–Weinberg equilibrium test p < 1 × 10–5. 
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After the quality control procedures, the experimental 
genotypes were phased using ShapeIT v2 and IMPUTE 
v2 was used for imputation analysis of the phased geno-
type data with 1000 Genomes Phase3 data as a reference 
panel. After imputation, imputed variants with imputa-
tion quality score < 0.4 or MAF < 1% were excluded from 
further analysis (Moon et  al., 2019, PMID 30718733). 
Finally, the number of SNPs for the GWAS was 7,975,321 
SNPs from chromosomes 1 to 22. We associated the clos-
est, or nearby genes of the significant variants as candi-
date genes utilizing LocusZoom.
Statistical analysis
All data are presented as the mean ± standard deviation 
(SD), or number (%). For the discovery GWAS analysis, 
the association between individual SNP genotypes and 
CAD, IS, and CCD risks were modeled additively for each 
copy of the minor allele using logistic regression adjusted 
for age, sex, BMI, exercise status, smoking status, alco-
hol intake, and PC1 and PC2 as covariates using PLINK, 
version 1.9 [16]. PC1 and PC2 were obtained through a 
principal component analysis, which was conducted to 
reduce the bias of genomic data due to the regional differ-
ences in sample collection. We selected high linkage dis-
equilibrium (LD) and cluster SNPs wherein no SNP gap 
exceeded 50 kb with high LD  (r2 > 0.8) from the top sig-
nificant SNPs. The significant associations were defined 
by genome-wide significance level p-values (5.00 × 10–8) 
[17]. The gene-region plot of the top SNP associations 
was generated with Locus- Zoom version 0.4.8.2 [18].
Results
Clinical characteristics of the 42,393 individuals included 
in the GWAS are shown in Table  1, and further details 
categorized by disease status are in Additional file  1: 
Tables S1–S3. A total of 16,309 individuals with HTN 
(56.1% female and 57.28 [7.45] years old), 5,314 with 
DM (50.9% female and 57.79 [7.39] years old), and 
20,770 with DL (58.4% female and 55.34 [7.63] years 
old) were included; the prevalence of CCD was 7.3% in 
HTN, 9.4% in DM, and 5% in DL, respectively. Results 
of the 9 GWASs are depicted in Fig.  2 as Manhattan 
plots using log10 transformed p-values. The leading 
SNPs in association with CAD, IS, and CCD for each 
group are described in Table 2. The full lists of genome-
wide significant (P-value < 5 × 10–8) and suggestive 
(5 × 10–8 ≤ P-value < 1 × 10–5) SNPs from the GWASs are 
available in Additional file 2: Tables S4–S6.
GWAS results of CVDs in Hypertension
The GWAS of HTN-CAD (Fig.  2a) showed 1 genome-
wide significant association locus (17q25.3) and 19 loci 
of suggestive association, HTN- IS (Fig.  2b) showed 
23 suggestive loci, and HTN-CCD (Fig.  2c) showed 
Fig. 1 Study Design. Flow diagram illustrating the study sample selection process and overall study design
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10 suggestive loci. The leading SNP of CAD in HTN 
(17q25.3/CBX8-CBX4 rs1550676) showed the strongest 
association (P = 6.37 × 10−9) and a high odds ratio (OR) 
of 2.607 (95% CI 1.886–3.602), and a total of 4 significant 
SNPs were clustered in the locus.
GWAS results of CVDs in DM
The GWAS of DM-CAD (Fig. 2d) showed 18 suggestive 
loci and that of DM-IS (Fig. 2e) showed 1 novel signifi-
cant locus (4q32.2) and 41 suggestive loci. In the GWAS 
of DM-CCD (Fig. 2f ), 1 locus, 17q25.3, was again shown 
to be significant with 21 suggestive loci. The leading SNP 
of CAD and CCD in DM (17q25.3/RPTOR rs139293840) 
showed strong associations (P = 1.99 × 10−8) as well as a 
high OR (3.511, 95%CI 2.265–5.444). The leading SNP 
for IS (4q32.3/MARCH1-LINC01207 rs149608518) also 
showed significance (P = 1.34 × 10−8) and a significantly 
high OR (5.587, 95%CI 3.086–10.12).
GWAS results of CVDs in DL
In DL, all 3 GWASs identified genome-wide significant 
loci: in DL-CAD (Fig. 2g), 1 significant locus (9q22.2) and 
24 suggestive loci; in DL-IS (Fig. 2h), 1 significant locus 
(3p22.1) and 40 suggestive loci; and in DL-CCD (Fig. 2i), 1 
significant locus (2p22.2) and 19 suggestive loci. A total of 
11 significant SNPs were clustered in 9q22.2/UNQ6494-
LOC10192784 associated with CAD, the lead SNP being 
rs79166762 (P = 7.78 × 10−9, OR = 2.282 [95% CI 1.724–
3.019]). 3p22.1/ULK4 rs3897976 showed significance 
for IS (P = 2.97 × 10−8, OR = 2.162 [95% CI 1.646–2.84]) 
and 2p22.2/CYP1B1-CYP1B1-AS1 rs189668056 for CCD 
(P = 4.24 × 10−8, OR = 2.027 [95% CI 1.574–2.609]).
Discussion
Despite large-scale GWASs providing robust evidence 
for genetic variants influencing metabolic pathways 
and CVDs, [19–24] it is unclear whether genetic vari-
ants exist for CVD within the basis of individual chronic 
metabolic diseases. The aim of our study was to identify 
genetic variations associated with CVD among individu-
als with HTN, DM, and DL, respectively; for which we 
found varied meaningful loci for CVD.
In HTN, locus 17q25.3 [CBX8-CBX4] showed the 
highest significance for CAD; intriguingly, 17q25.3 
was also found to uniformly show suggestive associa-
tions for CAD in both DM and DL, which shall be dis-
cussed in detail later. Candidate genes for HTN-CAD 
risk include CBX2/4/8, GAA, CARD14, and SLC26A11. 
Table 1 Clinical characteristics of the study population
Continuous variables are presented as mean (SD). Categorical variables are presented as No. (%)
Characteristics HTN DM DL
Number of individuals, No. 16,309 5314 20,770
Female, No. (%) 9146 (56.1%) 2706 (50.9%) 12,125 (58.4%)
Age, y 57.28 (7.45) 57.79 (7.39) 55.34 (7.63)
Coronary artery disease, No. (%) 816 (5.0%) 361 (6.8%) 768 (3.7%)
Ischemic stroke, No. (%) 398 (2.4%) 153 (2.9%) 295 (1.4%)
Cardio‑cerebrovascular disease, No. 
(%)
1185 (7.3%) 497 (9.4%) 1039 (5.0%)
Anthropometric traits
 Body mass index, kg/m2 25.04 (2.95) 25.12 (3.07) 24.68 (2.82)
 Waist circumference, cm 84.37 (8.38) 85.52 (8.44) 83.37 (8.28)
 Systolic blood pressure, mmHg 135.1 (14.58) 127.55 (14.93) 125.07 (14.64)
 Diastolic blood pressure, mmHg 83.2 (9.88) 77.48 (9.37) 77.33 (9.61)
Biochemical traits
 Fasting plasma glucose, mg/dl 100.28 (23.37) 132.7 (38.71) 98.73 (23.12)
 Total cholesterol, mg/dl 196.62 (36.79) 188.9 (40.78) 212.18 (43.92)
 HDL cholesterol, mg/dl 51.65 (12.72) 49.01 (11.9) 48.44 (13.8)
 Triglyceride, mg/dl 143.83 (95.78) 159.51 (119.82) 176.4 (114.14)
 LDL cholesterol, mg/dl 116.23 (34.5) 108.02 (37.21) 128.47 (42.28)
Lifestyle factors
 Smoking status: Never/Quit/Current, 
No. (%)
10,979 (67.3%)/ 3497 (21.4%)/ 
1833(11.2%)
3221 (60.6%)/ 1266 (23.8%)/ 
827(15.6%)
13,889 (66.9%)/ 3849 (18.5%)/ 
3032(14.6%)
 Drinking status: Never/Quit/Current, 
No. (%)
7965 (48.8%)/ 760 (4.7%)/ 7584(46.5%) 2629 (49.5%)/ 325(6.1%)/ 2360(44.4%) 10,592 (51%)/ 891 (4.3%)/ 
9287(44.7%)
 Exercise status: No/Yes, No. (%) 7924 (48.6%)/ 8385 (51.4%) 2633 (49.5%)/ 2681(50.5%) 10,040 (48.3%)/ 10,730 (51.7%)
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The CBX gene family, a recent research interest in the 
field of long noncoding RNAs, has been associated 
with CVD and atherosclerosis in multiple studies [25, 
26]. GAA gene expression has been found to be specifi-
cally increased in CAD patients than in controls [27]. 
CARD14, which is mainly associated with psoriasis 
(ongoing clinical studies suggest increased risk of CVDs 
in psoriasis) and auto-inflammatory disorders, acts as a 
pro-inflammatory gene by affecting NF-kB activation in 
the IL-17 inflammation pathway. Puig et al. [28] found 
that expression of genes such as CARD14 classified 
human atherosclerotic plaque by relative inflamma-
tion status. SLC26A11, a product of the SLC26A fam-
ily of anion transporters, has been associated with both 
Fig. 2 Manhattan Plots Showing Association Results of the GWASs. Manhattan plots showing association results from the GWASs of CVD in the 
HTN(A–C), DM(D–F), and DL(G–I) groups within the City Cohort: a HTN‑CAD (816 CAD cases and 15,488 controls), b HTN‑IS (398 IS cases and 
15,909 controls), c HTN‑CCD (1,185 CCD cases and 15,117 controls), d DM‑CAD (361 CAD cases and 5,161 controls), e DM‑IS (153 IS cases and 5,161 
controls), f DM‑CCD (497 CCD cases and 4,815 controls), g DL‑CAD (768 CAD cases and 19,999 controls), h DL‑IS (295 IS cases and 20,474 controls), 
and i DL‑CCD (1,039 CCD cases and 19,727 controls). Each tested SNP is visualized as a dot with a location on the genome shown on the x‑axis and 
log10‑ transformed p values on the y‑axis. Results for all chromosomes within the consensus threshold for genome‑wide significance (5 × 10−8) are 
marked with a horizontal line in red and suggestive significance (1 × 10–5) in blue
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cardiovascular and cerebrovascular disease; notably, it 
was postulated that SLC26A11 tagged multiple variants 
of RNF213 associated with young-onset IS [29], and 
SLC26A11 was detected from blood samples of patients 
with ST-elevation MI [30].
Interestingly, CARD14 and SLC26A11 in the region 
of 17q25.3 were located within 400 kb of the lead SNP 
for CCD in DM (17q25.3/RPTOR rs139293840) as 
well. HTN and DM share common risk factors and fre-
quently co-occur [31]; additionally, CVD is the most 
common long-term complication of both [6]. The over-
lapping association of SNPs and genetic loci between 
HTN and DM support the existence of shared points of 
regulation for these phenotypes [31].
RPTOR, RNF213, CARD14, and SLC26A11 all bear 
the potential to be the mechanism behind DM-CCD 
risk loci 17q25.3 [RPTOR]. RNF213 plays important 
roles in vascular development, and mutant RNF213 
has been shown to reduce angiogenesis and induce 
endothelial dysfunction [32]. RNF213 has been identi-
fied as a susceptibility gene of Moyamoya disease [33], 
intracranial arterial stenoses [34], and systemic vascu-
lopathy among East Asian populations [33] and CAD 
in the Japanese population [34]. Recently, the signifi-
cance of RNF213 and SLC26A11 in Caucasian popu-
lations were reported as well [29], which encourages 
its re-evaluation within other ethnicities. RPTOR is 
a component of the mTOR pathway, which regulates 
cell growth in response to nutrient levels by associat-
ing with the mammalian target of rapamycin (mTOR) 
[35]. New insights have been offered into RPTOR and 
CVD/atherosclerosis; such as evidence that miR-100 
exerts anti-angiogenic properties through suppression 
of mTOR, [25] and that inhibition of cardiac GSK-3β 
during continued myocardial ischemia attenuates 
ischemia-induced mTORC1 inhibition and increases 
ischemic injury [35].
Rs139293840 (17q25.3/RPTOR, minor allele frequency 
(MAF) ~ 0.01) showed substantial risk for DM-CAD (OR 
3.36 [2.06–5.48]); although the association was sugges-
tive (P = 1.27 × 10−6; however, genome-wide significance 
in DM-CCD, P = 1.99 × 10–8), this could be due to insuf-
ficient statistical power after selecting populations for 
quality control. Genetic risk factors regarding CAD have 
usually been found to have only a modest effect, con-
ferring an OR ranging from 1.05 to 1.20 [36]; consider-
ing the effect size, further replication studies with larger 
sample sizes are warranted. Based on genotyping data, 
the MAF of rs139293840 varies among different ethnic 
populations, ranging from 0.89% in Asians to 0.01% in the 
population of European ancestry to 0% in the American 
population. Thus, the association between rs139293840 
and CAD may be more prevalent in the Asian population.
The locus, 4p32.3 [MARCH1-LINC01207] showed 
significant risk for DM-IS (OR 5.587 [3.086–10.12]) and 
was located near APELA and MARCH1. APELA is a 
novel endogenous peptide ligand that activates the APJ 
receptor axis and is cardioprotective against HTN, MI, 
pulmonary arterial hypertension, and heart failure [37, 
38]. Recently, studies have shown that the apelin/APJ 
axis possess neuroprotective effects by inhibiting neu-
ronal apoptosis and improving functional recovery in 
IS through diverse mechanisms, including suppressing 
inflammatory responses, modulating autophagy, and pro-
moting angiogenesis [39]. MARCH1 has been identified 
as a susceptibility locus for MI and HTN in Japanese [40], 
and regarding IS, was included as 1 of the 31 SNPs sig-
nificantly associated with IS in an initial EWAS [41].
In DL-CAD risk, locus 9q22.2 [UNQ6494-
LOC10192784] was significant; Semaphorin 4D 
(SEMA4D) and Growth arrest and DNA-damage-induc-
ible 45 (GADD45G) are potential candidates. Sema4D 
is a type I integral membrane glycoprotein expressed by 
most hematopoietic cells that participate in the patho-
genesis of atherosclerosis, which has been identified as 
an independent risk factor for CHD [42]. GADD45G, of 
the GADD45 family involved in p38 mitogen-activated 
protein kinase-dependent cell death, has been linked 
with several cardiologic studies [43]. Recently, conferred 
resistance to myocardial ischemic injury and cardiomyo-
cyte apoptosis was found when GADD45G was deleted in 
mice [44].
Again, the gene-rich locus 17q25.3 was found to be of 
suggestive association for CAD in DL. Considering the 
small sample size, we consider this finding to bear signifi-
cance, which confers on 17q25.3 the status of a common 
susceptibility locus of CVD in HTN, DM, and DL. It has 
not been fully elucidated whether these chronic meta-
bolic diseases are part of the causal pathway for CVD or 
merely comorbid diseases in “common soil”. The search 
has been fraught with controversial findings, as has the 
presence of overlap in the genetic architecture of meta-
bolic diseases and CVDs. This study provides first prob-
able evidence of a common candidate locus for CVD in 
the 3 diseases using a GWAS approach.
Locus 3p22.1 [ULK4] of DL-IS risk seems likely to be 
associated with ULK4; recently, ULK4 was identified by 
GWAS and brain eQTL to be a susceptibility gene for 
IS and small vessel stroke in trans-ethnic datasets [45]. 
However, CTNN1B of the WNT gene family is another 
possibility. The Wnt signaling pathway contributes to 
the development of CVDs; both canonical and nonca-
nonical Wnt signaling cascades moderate cell phenotypic 
modulation of vascular smooth muscles in CVDs [46]. 
CTNN1B encodes beta-catenin and is essential in main-
taining CNS homeostasis [47]; in terms of arteriosclerotic 
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effects, CTNN1B was found to harbor a susceptibil-
ity variant for MI in the Han population [48]. Recently, 
expression of vital genes in the Wnt pathway (including 
CTNN1B) was found to be upregulated in cerebral infarc-
tion in rats [46]; it seems plausible that similar findings 
could be found in humans.
Finally, 2p22.2 [CYP1B1-CYP1B1-AS1] of DL-
CCD risk could be associated with Cytochrome P450 
1B1(CYP1B1), a member of the well-known Cytochrome 
P450 family. CYP1B1 is expressed in various tissues, with 
the highest mRNA expression levels found extrahepati-
cally, such as the heart and brain [49]. Recent findings 
have shown that CYP1B1 contributes to the development 
of atherosclerosis, DL, and HTN in rats [50]; demon-
strates an association with DM [51]; and has a suggested 
influence on adipogenesis [49].
Strengths and limitations
There are limitations to our study. First, replication 
is lacking, and the findings may not be generalized to 
cohorts with different ethnicities and races. Second, we 
investigated the phenotypes of diseases using a patient-
reported questionnaire and thus could not investigate 
various CVDs or measurable continuous traits. Third, 
this work is based on statistical evidence and does not 
provide functional experimental validation. Poten-
tial genetic interactions using biological and mechani-
cal analyses are required to confirm these findings, and 
additional studies are warranted for replication and 
validation.
Despite these limitations, our study has several unique 
strengths. Many studies have demonstrated varied find-
ings regarding the genetic relations between CVD and 
its risk factors [52–54]. However, most previous studies 
utilized variants of genome-wide significance or geno-
typing arrays that focused only on pre-selected loci, and 
they have not fully utilized genome-wide variation for 
the estimation of genetic variants of CVD risk [55–57]. 
Moreover, none of these previous studies have focused 
on the genetic variants of CVD within the same chronic 
conditions. To the best of our knowledge, the present 
study provides novel evidence of genetic associations 
with CVD specific to individuals with HTN, DM, and 
DL. Charmet et al. [58] found novel candidates for CAD 
using a then unprecedented similar study design (434 
cases and 3,123 controls), in patients with type 1 diabe-
tes. The barrier of limited statistical power due to sample 
size may be why such studies are lacking.
Although some of our findings showed low preva-
lence, the overall effect size is significant with high ORs. 
Also, the allele frequency may be underestimated due to 
smaller quality genomic databases of East Asians used in 
forming the reference panels. Further, cardio-metabolic 
diseases associated with CVDs have been increasing in 
prevalence as well as in total medical costs in Asians, 
with HTN and DM ranking 1st and 2nd among all medi-
cal diagnoses in Korea, respectively [59]. Dyslipidemia 
prevalence has been rapidly increasing up to 38.4% of all 
adults, and CVDs account for 1/4 of total mortality of 
the Korean population according to recent data [60]. Our 
preliminary findings may be used to improve the identi-
fication of individuals with HTN, DM, or DL at high-risk 
for cardiovascular events or to provide novel targets for 
potential pharmacologic development. In the era of per-
sonalized, preventive medicine with progressively aging 
populations with chronic cardio-metabolic diseases, fur-
ther comprehensive analyses of our findings seem highly 
warranted.
Conclusions
In conclusion, our GWAS, of unprecedented design, pro-
vides several novel insights into the genetic architecture 
of CVDs. We report 6 loci with genome-wide significant 
association for CVDs, which harbor numerous potential 
positional candidate genes, and show substantial CVD 
risk discrimination in individuals with HTN, DM, or DL. 
In addition, we suggest the importance of 17q25.3 as a 
potential common CAD locus for HTN, DM, and DL.
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